Gara Jalqabaatti › Leukemia Myeloidii Hamaa › Maryland › Baltimore
Qorannoo klinikaalii Leukemia Myeloidii Hamaa Baltimore, MD keessatti
Qorannoo 19 Leukemia Myeloidii Hamaa f Baltimore fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Namoota walitti qabaa jiraSadarkaa 2
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Namoota walitti qabaa jiraSadarkaa jalqabaa 1
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
- Mercy Medical Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
- fi 2 dabalataa
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Namoota walitti qabaa jiraSadarkaa 1
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
Namoota walitti qabaa jiraSadarkaa 1/2
- Johns Hopkins University, Baltimore
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Namoota walitti qabaa jiraSadarkaa 3
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
Namoota walitti qabaa jiraSadarkaa 2
- John Hopkins School of Medicine, Baltimore
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Namoota walitti qabaa jiraSadarkaa 3
- US-Baltimore MD-UMGCCC, Baltimore
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
Namoota walitti qabaa jiraSadarkaa 3
- US-Baltimore MD-UMGCCC, Baltimore
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Namoota walitti qabaa jiraSadarkaa 1/2
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
Namoota walitti qabaa jiraSadarkaa 1
- University of Maryland/Greenebaum Cancer Center, Baltimore
Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies
Namoota walitti qabaa jiraSadarkaa 1
- Tania Jain, MD, Baltimore
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Namoota walitti qabaa jiraSadarkaa 3
- University of Maryland Medical Center (UMMC), Baltimore
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Namoota walitti qabaa jiraQorannoo ilaalaa
- Johns Hopkins, Baltimore
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
Namoota walitti qabaa jiraSadarkaa 2
- University of Maryland Greenebaumn Comprehensive Cancer Center, Baltimore
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Namoota walitti qabaa jiraSadarkaa 1/2
- Sibley Memorial Hospital, Baltimore
- University of Maryland, Baltimore
- Johns Hopkins Main Center, Baltimore
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Namoota walitti qabaa jiraSadarkaa 1
- Johns Hopkins School of Medicine, Baltimore
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
- Johns Hopkins University, Baltimore
Qorannoo Leukemia Myeloidii Hamaa magaalota biroo keessatti
- Houston, TXQorannoo 85
- New York City, NYQorannoo 51
- Boston, MAQorannoo 44
- Seattle, WAQorannoo 41
- Baldwin Park, CAQorannoo 40
- Columbus, OHQorannoo 35
- Philadelphia, PAQorannoo 34
- Durham, NCQorannoo 33
- Atlanta, GAQorannoo 31
- Tampa, FLQorannoo 29
- Chicago, ILQorannoo 26
- Portland, ORQorannoo 25
Qorannoo biroo Baltimore keessatti
- Kansara Qara'a Non-Small CellQorannoo 60
- Saree OljooQorannoo 47
- Kansarii ProstateQorannoo 43
- Dhibee QaraQorannoo 40
- Saree (Gosoota Hunda)Qorannoo 37
- Kansarii PancreasQorannoo 31
- Kansarii ColorectalQorannoo 31
- Kansara MetastatikiiQorannoo 28
- ObesityQorannoo 26
- Dukkana BladderQorannoo 24
- Cufama OnneeQorannoo 24
- Kansarii OvariiQorannoo 22
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.